|Abstract:||The invention relates to a compound, and pharmaceutically acceptable salts, having the formula I: ##STR1## wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C.sub.1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl, R.sup.1 represents hydrogen, trifluoro (C.sub.1-4) alkyl, alkyl or alkynyl, X represents hydrogen, alkyl having 1-4 carbon atoms, alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio or aralkoxy, R.sup.2 represents: a C1-C10 alkyl group, a phenyl group optionally substituted by one or more of the following groups: a C1-C10 alkyl group, a halogen group, a nitro group, hydroxy group, and/or an alkoxy group.|
|Inventor(s):||Benneker; Franciscus Bernardus Gemma (Nijmegen, NL), Van Dalen; Frans (Nuenen, NL), Lemmens; Jacobus Maria (Mook, NL), Peters; Theodorus Hendricus Antonium (Arnhem, NL), Picha; Frantisek (Brno, CZ)|
|Assignee:||Synthon BCT Technologies, LLC (Chapel Hill, NC)|
|Filing Date:||May 16, 2001|
|Claims:||1. A process for preparing paroxetine hydrochloride comprising contacting paroxetine methanesulfonate and hydrochloric acid and thereby forming paroxetine hydrochloride. |
2. The process according to claim 1, wherein said paroxetine methane sulfonate is crystalline.
3. The process according to claim 2, wherein said crystalline paroxetine methane sulfonate was prepared by crystallizing paroxetine methane sulfonate from ethyl acetate.